Amyloid

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Retrieved on: 
Tuesday, August 22, 2023

She is first told it’s nothing to worry about, then, a year later, that it’s “just normal aging.” Until finally, the penny drops: “It’s Alzheimer’s.

Key Points: 
  • She is first told it’s nothing to worry about, then, a year later, that it’s “just normal aging.” Until finally, the penny drops: “It’s Alzheimer’s.
  • Dementia remains largely underdetected, even in high-income countries such as Canada where rates of undetected cases exceed 60 per cent.
  • Research has shown that people with mild changes in cognition are at a greater risk of developing dementia later in life.
  • Despite this, protocols for early detection are not standard in the medical community, in part because significant gaps remain in our understanding of dementia.

Dementia and an aging population

    • In my research, I use advanced brain MRI methods to characterize brain health in older adults who are at high risk of developing dementia.
    • The goal is to identify new biomarkers of early pathology, which could lead to improved detection methods in the future.
    • The proportion of senior Canadians is growing in our population.
    • Dementia is strongly associated with aging, so the number of Canadians diagnosed with dementia — including Alzheimer’s — is expected to rise considerably in the next few decades, reaching an expected 1.7 million Canadians by 2050.

Lifestyle and brain health

    • By making dementia risk assessment a part of routine medical visits for older adults, those who are most at risk could be identified and counselled on how to maintain brain health and cognition.
    • At-risk individuals likely need those interventions the most (potentially a combination of pharmaceutical and lifestyle interventions), but anyone can benefit from adopting healthy lifestyle habits, which are known to protect from diseases not only of the brain, but also of the heart and other organs.
    • Some evidence also suggests that a Mediterranean diet, which emphasizes high consumption of plants (especially leafy greens) while reducing saturated fats and meat intake, is also beneficial for brain health.

Barriers to healthy lifestyles

    • Policy changes could address these inequalities not only by promoting healthy lifestyles, but also by taking action to improve the circumstances in which people of these communities live.
    • Examples include improving access to sport centres or prevention clinics for people with lower incomes and designing cities that are conducive to active lifestyles.
    • Governments need to evaluate and address the barriers that prevent people from specific groups from adopting healthy lifestyle habits.

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

Retrieved on: 
Thursday, August 17, 2023

C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.
  • In a clinical validation study involving two independent cohorts totaling 583 patients with cognitive impairment using amyloid PET as the reference standard, the PrecivityAD2 blood test achieved an overall test performance statistic of 0.94 AUC and 88% accuracy.
  • The PrecivityAD2 blood test simultaneously quantifies specific plasma amyloid beta and tau peptide concentrations to calculate the Aβ42/40 Ratio and p-tau217/np-tau217(p-tau217 Ratio).
  • In this regard, the PrecivityAD2 blood test makes a significant contribution to the diagnosis of patients with Alzheimer’s disease.

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Retrieved on: 
Thursday, July 20, 2023

This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.

Key Points: 
  • This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.
  • The U.S. Food and Drug Administration (FDA) granted traditional approval for LEQEMBI for the treatment of Alzheimer's disease (AD) on July 6, 2023.
  • In an exposure/bioavailability and modeling study comparing intravenous (IV) and subcutaneous (SC) dosing of lecanemab, the bioavailability of SC dosing of lecanemab was shown to be approximately 50% of that of IV dosing.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

New Diagnostics and Emerging Biomarkers for Alzheimer's Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, August 7, 2023

TORONTO, Aug. 7, 2023 /PRNewswire-PRWeb/ -- In an exciting development for Alzheimer's disease research, esteemed experts in the field from Labcorp will present a comprehensive webinar titled "New Diagnostics and Emerging Biomarkers for Alzheimer's Disease." This webinar will illuminate recent advancements, discuss the establishment of the ATN research framework and delve into how this new paradigm is revolutionizing the understanding and treatment of Alzheimer's disease.

Key Points: 
  • The featured speakers will describe the relationship between various biomarkers — including emerging biomarkers — and how these are enabling advancements in Alzheimer's disease research.
  • TORONTO, Aug. 7, 2023 /PRNewswire-PRWeb/ -- In an exciting development for Alzheimer's disease research, esteemed experts in the field from Labcorp will present a comprehensive webinar titled "New Diagnostics and Emerging Biomarkers for Alzheimer's Disease."
  • As part of their commitment to advancing the medical field, they have formed a strategic partnership with Xtalks to present this vital webinar.
  • The webinar, "New Diagnostics and Emerging Biomarkers for Alzheimer's Disease," will take place on Thursday, August 24, 2023, at 11am EDT (4pm BST/UK).

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 3, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2023 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2023 and provided business highlights.
  • For the second quarter and first six months of 2023, Prothena reported net loss of $54.6 million and $101.5 million, as compared to a net loss of $41.2 million and $77.5 million for the second quarter and first six months of 2022.
  • Research and development (R&D) expenses totaled $56.0 million and $100.8 million for the second quarter and first six months of 2023, as compared to $31.6 million and $58.8 million for the second quarter and first six months of 2022, respectively.
  • Total non-cash share-based compensation expense was $10.1 million and $18.9 million for the second quarter and first six months of 2023, as compared to $8.3 million and $15.9 million for the second quarter and first six months of 2022.

Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 3, 2023

ET / 1:30 p.m. PT

Key Points: 
  • ET / 1:30 p.m. PT
    SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2023 financial results and recent portfolio and business updates.
  • Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) in July 2023.
  • In the second quarter of 2023, the U.S. Patent and Trademark Office issued patents covering methods of treatment using AL002.
  • Alector’s management team will host a conference call discussing Alector’s results for the second quarter of 2023 and provide a business update.

Alzheimer’s Disease Community Benefits as C2N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard

Retrieved on: 
Wednesday, August 2, 2023

C2N Diagnostics says it further bolstered its role as a leader in advanced brain health diagnostics at the Alzheimer’s Association International Conference® (AAIC®) 2023 in Amsterdam.

Key Points: 
  • C2N Diagnostics says it further bolstered its role as a leader in advanced brain health diagnostics at the Alzheimer’s Association International Conference® (AAIC®) 2023 in Amsterdam.
  • The presentations included information on the company’s pipeline product, PrecivityAD2, along with other Precivity-related analytes that are setting a new standard in blood biomarker innovation and diagnostic performance.
  • The PrecivityAD2 test uses a proprietary Amyloid Probability Score 2 (APS2) result that incorporates precise measurements of p-tau217/np-tau217 Ratio and Aβ42/40 Ratio into an analytically and clinically validated algorithm.
  • “We’ve shown that primary care doctors could gain access to a blood biomarker test with high test performance to detect Alzheimer’s disease pathology.

UT Health Science Center San Antonio study will assess Mexican Americans and dementia risk

Retrieved on: 
Wednesday, August 2, 2023

SAN ANTONIO, Texas, Aug. 2, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio has received a five-year, $15.5 million grant to conduct the San Antonio Heart and Mind Study, an investigation of why the region's older Mexican Americans experience a higher rate of dementia than older non-Hispanic white adults. The National Institutes of Health/National Institute on Aging awarded the funding.

Key Points: 
  • The San Antonio Heart and Mind Study is an extension of previous groundbreaking research conducted by the health science center.
  • SAN ANTONIO, Texas, Aug. 2, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio has received a five-year, $15.5 million grant to conduct the San Antonio Heart and Mind Study, an investigation of why the region's older Mexican Americans experience a higher rate of dementia than older non-Hispanic white adults.
  • She will conduct the study with colleagues of UT Health San Antonio's Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases.
  • The new research is an extension of the San Antonio Heart Study conducted at UT Health San Antonio between 1979 and 2006.

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Retrieved on: 
Thursday, July 20, 2023

TOKYO and CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI®) treatment showed reductions in amyloid-beta (Aβ) pathology and downstream biomarker changes. This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023. The U.S. Food and Drug Administration (FDA) granted traditional approval for LEQEMBI for the treatment of Alzheimer's disease (AD) on July 6, 2023.

Key Points: 
  • This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.
  • These outcomes suggested lecanemab impacts A/T/N+ biomarkers involved in the AD pathophysiology and exerts biological effects that demonstrate slowing of disease progression.
  • In an exposure/bioavailability and modeling study comparing intravenous (IV) and subcutaneous (SC) dosing of lecanemab, the bioavailability of SC dosing of lecanemab was shown to be approximately 50% of that of IV dosing.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

SIMPLE FINGER PRICK TEST EXEMPLIFIES ADVANCES IN ALZHEIMER'S DISEASE BLOOD TESTS

Retrieved on: 
Wednesday, July 19, 2023

AMSTERDAM, July 19, 2023 /PRNewswire/ -- A simple, finger prick blood test — not so different from what people with diabetes do every day — shows promise in the ability to detect Alzheimer's disease, according to research reported for the first time today at the Alzheimer's Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online.

Key Points: 
  • Results from a simple, finger prick blood test are promising and may help detect Alzheimer's at home or in the doctor's office.
  • They collected blood (from both vein and finger prick) from 77 memory clinic patients from the ACE Alzheimer Center, Barcelona.
  • GFAP, NfL and p-tau217 extracted from finger prick blood also correlated highly with standard blood collection.
  • Blood tests for Alzheimer's disease have great potential for improving diagnostic accuracy and proper treatment of people with Alzheimer's.